Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-Blind, Triple-Dummy, Placebo-Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg QD Versus Montelukast 10mg QD in Adolescent and Adult Subjects With Asthma and Seasonal Allergic Rhinitis Who Are Receiving ADVAIR DISKUS® 100/50mcg BID or Placebo BID
Brief Summary: This study will last up to 6 weeks. Subjects will visit the clinic up to 5 times. Certain clinic visits will include a physical examination, medical history review, and lung function tests. All study related medications and medical examinations will be provided at no cost to the subject. The drugs used in this study are approved for the age group under study.


Options:
A: Intervention Type: BEHAVIORAL; Name: Shared-Decision Making; Assigned to Arm(s): N/A
B: Arm Label: Fluticasone Propionate/Salmeterol/Montelukast (FSC+MON); Type: ACTIVE_COMPARATOR; Interventions: Drug: fluticasone propionate/salmeterol (FSC), Drug: montelukast (MON), Drug: placebo nasal, Drug: ADVAIR DISKUS | Arm Label: Fluticasone Propionate/Salmeterol (FSC); Type: ACTIVE_COMPARATOR; Interventions: Drug: fluticasone propionate/salmeterol (FSC), Drug: placebo nasal, Drug: ADVAIR DISKUS, Drug: placebo capsule | Arm Label: Fluticasone Prop/Salmeterol/Flut Prop Nasal Spray (FSC+FPANS); Type: ACTIVE_COMPARATOR; Interventions: Drug: fluticasone propionate/salmeterol (FSC), Drug: fluticasone propionate (FP), Drug: ADVAIR DISKUS, Drug: placebo capsule | Arm Label: Montelukast (MON); Type: ACTIVE_COMPARATOR; Interventions: Drug: montelukast (MON), Drug: placebo nasal, Drug: placebo DISKUS | Intervention Type: DRUG; Name: fluticasone propionate/salmeterol (FSC); Assigned to Arm(s): Fluticasone Prop/Salmeterol/Flut Prop Nasal Spray (FSC+FPANS), Fluticasone Propionate/Salmeterol (FSC), Fluticasone Propionate/Salmeterol/Montelukast (FSC+MON) | Intervention Type: DRUG; Name: montelukast (MON); Assigned to Arm(s): Fluticasone Propionate/Salmeterol/Montelukast (FSC+MON), Montelukast (MON) | Intervention Type: DRUG; Name: fluticasone propionate (FP); Assigned to Arm(s): Fluticasone Prop/Salmeterol/Flut Prop Nasal Spray (FSC+FPANS) | Intervention Type: DRUG; Name: placebo nasal; Assigned to Arm(s): Fluticasone Propionate/Salmeterol (FSC), Fluticasone Propionate/Salmeterol/Montelukast (FSC+MON), Montelukast (MON) | Intervention Type: DRUG; Name: ADVAIR DISKUS; Assigned to Arm(s): Fluticasone Prop/Salmeterol/Flut Prop Nasal Spray (FSC+FPANS), Fluticasone Propionate/Salmeterol (FSC), Fluticasone Propionate/Salmeterol/Montelukast (FSC+MON) | Intervention Type: DRUG; Name: placebo capsule; Assigned to Arm(s): Fluticasone Prop/Salmeterol/Flut Prop Nasal Spray (FSC+FPANS), Fluticasone Propionate/Salmeterol (FSC) | Intervention Type: DRUG; Name: placebo DISKUS; Assigned to Arm(s): Montelukast (MON)
C: Arm Label: FP/SAL 250/50mcg BID plus GSK2190915 300mg QD (AM); Type: EXPERIMENTAL; Interventions: Drug: FP/SAL 250/50mcg BID, Drug: GSK2190915 200mg QD (AM), Drug: GSK2190915 100mg QD (AM), Drug: Placebo capsule (PM) | Arm Label: FP/SAL 250/50mcg BID plus montelukast 10mg QD (PM); Type: ACTIVE_COMPARATOR; Interventions: Drug: FP/SAL 250/50mcg BID, Drug: Montelukast 10mg QD (PM), Drug: Placebo tablets (2) (AM) | Arm Label: FP/SAL 250/50mcg BID plus placebo BID; Type: PLACEBO_COMPARATOR; Interventions: Drug: FP/SAL 250/50mcg BID, Drug: Placebo tablets (2) (AM), Drug: Placebo capsule (PM) | Intervention Type: DRUG; Name: FP/SAL 250/50mcg BID; Assigned to Arm(s): FP/SAL 250/50mcg BID plus GSK2190915 300mg QD (AM), FP/SAL 250/50mcg BID plus montelukast 10mg QD (PM), FP/SAL 250/50mcg BID plus placebo BID | Intervention Type: DRUG; Name: GSK2190915 200mg QD (AM); Assigned to Arm(s): FP/SAL 250/50mcg BID plus GSK2190915 300mg QD (AM) | Intervention Type: DRUG; Name: GSK2190915 100mg QD (AM); Assigned to Arm(s): FP/SAL 250/50mcg BID plus GSK2190915 300mg QD (AM) | Intervention Type: DRUG; Name: Montelukast 10mg QD (PM); Assigned to Arm(s): FP/SAL 250/50mcg BID plus montelukast 10mg QD (PM) | Intervention Type: DRUG; Name: Placebo tablets (2) (AM); Assigned to Arm(s): FP/SAL 250/50mcg BID plus montelukast 10mg QD (PM), FP/SAL 250/50mcg BID plus placebo BID | Intervention Type: DRUG; Name: Placebo capsule (PM); Assigned to Arm(s): FP/SAL 250/50mcg BID plus GSK2190915 300mg QD (AM), FP/SAL 250/50mcg BID plus placebo BID
D: Arm Label: Montelukast/Salmeterol; Type: EXPERIMENTAL; Interventions: Drug: Montelukast sodium, Drug: Salmeterol xinafoate, Drug: Fluticasone propionate, Drug: Montelukast matching placebo, Drug: Salmeterol matching placebo | Arm Label: Salmeterol/Montelukast; Type: EXPERIMENTAL; Interventions: Drug: Montelukast sodium, Drug: Salmeterol xinafoate, Drug: Fluticasone propionate, Drug: Montelukast matching placebo, Drug: Salmeterol matching placebo | Intervention Type: DRUG; Name: Montelukast sodium; Assigned to Arm(s): Montelukast/Salmeterol, Salmeterol/Montelukast | Intervention Type: DRUG; Name: Salmeterol xinafoate; Assigned to Arm(s): Montelukast/Salmeterol, Salmeterol/Montelukast | Intervention Type: DRUG; Name: Fluticasone propionate; Assigned to Arm(s): Montelukast/Salmeterol, Salmeterol/Montelukast | Intervention Type: DRUG; Name: Montelukast matching placebo; Assigned to Arm(s): Montelukast/Salmeterol, Salmeterol/Montelukast | Intervention Type: DRUG; Name: Salmeterol matching placebo; Assigned to Arm(s): Montelukast/Salmeterol, Salmeterol/Montelukast

Answer: B